Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis.
All News
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.
Novel Imaging of Skin Disease in Scleroderma
An emerging technique called spatial frequency domain imaging (SFDI) proved its mettle for evaluating skin fibrosis in systemic sclerosis (SSc), also called scleroderma, in an early clinical study.
Dr. Jack Cush reviews this week's news from RheumNow.com, including: placebo trumps controversial therapies, the dynamics of disease activity, fuse the big toe, and patients don’t appreciate being told “it's all in your head”!
